Shwachman-Diamond Syndrome
A rare inherited disorder combining pancreatic insufficiency, bone marrow failure, and skeletal abnormalities, with a long-term risk of MDS and AML.
- Inherited marrow failure syndrome
- Pancreatic enzyme management
- Stem cell transplant access
- Typical Age at Diagnosis
- Infancy to early childhood
- Inheritance
- Autosomal recessive
- Key Risk
- Progression to MDS/AML
- Advanced Therapies
- Stem cell transplant
What Is Shwachman-Diamond Syndrome?
Shwachman-Diamond syndrome (SDS) is a rare inherited disorder that primarily affects the pancreas and bone marrow. Most children present in infancy with poor growth and fatty, foul-smelling stools caused by exocrine pancreatic insufficiency, often alongside low neutrophil counts that predispose to recurrent infections.
The condition is most commonly caused by mutations in the SBDS gene, with a smaller number of cases linked to DNAJC21 or EFL1. Many affected individuals also have skeletal abnormalities, short stature, and, less commonly, heart or liver involvement.
A central long-term concern is bone marrow failure, which can progress over time and carries an elevated risk of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), making lifelong hematologic surveillance an essential part of care.
Genetic and Clinical Subtypes
Shwachman-Diamond syndrome is genetically heterogeneous, with the underlying gene influencing certain disease features.
Symptoms and Signs
Symptoms typically appear in infancy and reflect both pancreatic and bone marrow involvement.
Causes and Risk Factors
SDS is caused by inherited mutations affecting ribosome biogenesis, which disrupts normal cell function in the pancreas and bone marrow.
Diagnosis and Investigations
Diagnosis combines evaluation of pancreatic function, blood counts, and genetic confirmation.
Disease Risk Stratification
SDS is not formally staged, but hematologic risk is stratified based on marrow findings and cytogenetics.
Standard Treatment Approach
Management addresses both pancreatic insufficiency and bone marrow risk through a coordinated, lifelong care plan.
Advanced and Emerging Treatment Options
While most pancreatic symptoms are managed with enzyme replacement, hematologic complications may require more advanced intervention.
Cellular Therapy
Allogeneic Hematopoietic Stem Cell Transplant
The only curative treatment for severe marrow failure or transformation to MDS/AML in SDS.
Growth Factor Therapy
Granulocyte Colony-Stimulating Factor (G-CSF)
Used selectively for significant neutropenia with recurrent infections, though chronic use requires careful marrow monitoring.
Precision Medicine
Genetic Subtype Counseling
Identifying the specific gene (SBDS, DNAJC21, EFL1) helps anticipate associated features and tailor surveillance.
Research
Ribosome Biogenesis-Targeted Research
Ongoing research into the underlying ribosomal defect may eventually inform future targeted approaches, though this remains investigational.
Biomarkers and Precision Medicine
Genetic and marrow findings help guide surveillance and treatment decisions.
When a Second Opinion May Be Important
Specialist input can clarify management at key points in the disease course.
Clinical Trials and Research
Prognosis and Key Outcome Factors
Many individuals with Shwachman-Diamond syndrome experience improving pancreatic function over childhood, but lifelong hematologic surveillance remains important because of the long-term risk of bone marrow failure and leukemic transformation.
Supportive Care and Living With Shwachman-Diamond Syndrome
Coordinated, lifelong follow-up supports growth, nutrition, and early detection of marrow complications.
How CancerFax Helps You Explore Treatment Options
We help families with Shwachman-Diamond syndrome access specialist review of marrow and genetic reports, connect with experienced hematology centers, and coordinate second opinions when transplant is being considered.
Get a free case reviewFrequently Asked Questions
It is a rare inherited disorder affecting the pancreas and bone marrow, causing poor nutrient absorption, low blood counts, and an elevated long-term risk of MDS or AML.
Early signs often include poor weight gain, fatty stools, and recurrent infections related to low neutrophil counts in infancy.
Most cases are caused by mutations in the SBDS gene, with a smaller number caused by DNAJC21 or EFL1 mutations.
In many patients, pancreatic function improves with age, though enzyme replacement may still be needed; bone marrow risk persists regardless.
Diagnosis combines pancreatic function testing, blood counts, bone marrow examination, and genetic testing.
Yes, there is an elevated lifetime risk of progression to MDS or AML, which is why regular bone marrow surveillance is recommended.
There is no cure for the underlying genetic defect, but allogeneic stem cell transplant can cure the hematologic component in those who develop severe marrow failure or MDS/AML.
Most specialists recommend periodic bone marrow exams with cytogenetics, often annually, depending on individual risk.
Yes, it is inherited in an autosomal recessive pattern, meaning both parents typically carry one altered gene copy.
Yes. CancerFax can help you arrange specialist review of medical and genetic reports, connect with experienced hematology centers, and coordinate second opinions and cross-border care when needed.
Get Specialist Guidance for Shwachman-Diamond Syndrome
Send your reports for review and explore treatment and second-opinion options with experienced specialists.